Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Alimentary pharmacology & therapeutics
- Publicado em
- 26 set 2023
- Citações
- 45
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease
Ronnie Fass, Michael Vaezi, Prateek Sharma, Rena Yadlapati, Barbara Hunt, Tom Harris, Neila Smith, Eckhard Leifke, David Armstrong
Descritores MeSH
- Gastroesophageal Reflux
- Heartburn
- Humans
- Pyrroles
- Sulfonamides
- Treatment Outcome
- Proton Pump Inhibitors
Veja também
Estudos relacionados
- Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis
- Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
- Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease
- Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor